`
`Patent Assignment Agreement
`
`THIS PATENT ASSIGNMENT AGREEMENT is entered into as of September 8, 2017
`("Effective Date”) by and between Allergan. Inc. a Delaware corporation ('Assignor"). and
`Saint Regis Mohawk Tribe, a federally recognized sovereign Native American Tribe
`('Assignee“). Each of Assignor and Assignee are referred to herein as a “Party” and,
`collectively, they are referred to herein as the "Parties”.
`
`WHEREAS, Assignor is the sole and exclusive owner of the US. Patents and pending patent
`applications identified in Exhibit A (the ”Assigned Patents"); and
`
`WHEREAS, Assignee desires to acquire all rights, title and interest in and to the Assigned
`Patents:
`
`NOW, THEREFORE, the parties agree as follows:
`
`1. Assignment Be it known that for good and valuable consideration, the receipt and
`sufficiency of which is hereby acknowledged, and subject to the encumbrances
`identified herein. Assignor hereby irrevocably conveys, transfers. and assigns to
`Assignee, and Assignee hereby accepts, all of Assignor's right. title, perogatives,
`benefits, and interest in and to the following:
`
`(a) the Assigned Patents; and
`
`(b) all rights, including any ownership claims or beneficial
`rights, of any kind whatsoever of Assignor that have
`accrued, or that may accrue now or in the future, under any
`of the Assigned Patents provided by applicable law of any
`jurisdiction, by international treaties and conventions. and
`otherwise throughout the world (“Other Rights”); provided
`that such Other Rights excludes any license or agreement
`entered into by the Parties on or after the Effective Date.
`
`2. Representations and Warranties of Assignor. Assignor hereby represents and
`warrants to Assignee, as of the date hereof, that:
`
`a. Assignor has all requisite power and authority, corporate or otherwise, to
`execute, deliver, and perform this Patent Assignment Agreement.
`
`b. The execution and delivery of this Patent Assignment Agreement and the
`performance by Assignor of the transactions contemplated hereby have been
`duly authorized by all necessary corporate action. and do not violate: (a) in
`any material respect, any agreement. instrument, or contractual obligation to
`which Assignor is bound; (b) any requirement of any Applicable Law: or
`[c] any order, writ, judgment, injunction, decree, determination. or award of
`any court or Governmental Entity presently in effect applicable to Assignor.
`
`1
`
`0““? fif/E/H
`/
`_,
`3f
`’1“, “a;
`
`.
`
`ALL 2086
`MYLAN PHARMACEUTICALS V. ALLERGAN
`lPR2016-01 127
`
`
`
`EXECUTION VERSION
`
`c. This Patent Assignment Agreement is a legal, valid, and binding obligation of
`Assignor enforceable against it in accordance with its terms and conditions,
`subject to the effects of bankruptcy, insolvency, or other laws ofgeneral
`application affecting the enforcement ofcreditor rights, judicial principles
`affecting the availability ofspecific performance, and general principles of
`equity (whether enforceability is considered a proceeding at law or equity).
`
`d. Assignor is the sole and exclusive owner of the Assigned Patents.
`
`3. Encumbrances.
`
`a. Prior to the execution ofthis Assignment. Assignor and/or its affiliates have
`entered into certain settlement agreements and convenants not to sue
`(“Settlement Agreements") with certain third parties ("Settlement
`Parties") regarding one or more ofthe Assigned Patents in which license
`rights under the Assigned Patents were granted to the Settlement Parties and
`their affiliates and/or successors. The Settlement Agreements are set forth
`on Schedule 33.
`
`b. For the avoidance of doubt, the Parties individually and mutually agree that
`this assignment ofthe Assi ned Patents does not assi n an Settlement
`
`Agreement to Assignee.
`
`4. Representations and Warranties of Assignee.
`
`a. Assignee has all requisite power and authority, corporate or otherwise, to
`execute, deliver, and perform this Patent Assignment Agreement.
`
`b. The execution and delivery of this Patent Assignment Agreement and the
`performance by Assignee of the transactions contemplated hereby have been
`duly authorized by all necessary tribal action, and do not violate: (a) in any
`material respect, any agreement. instrument, or contractual obligation to
`which such Assignee is bound; (b) any requirement ofany Applicable Law; or
`
`2
`
`M” £7397 /’9
`arr m,.>5¢/'
`
`
`
`EXECUTION VEMION
`
`(c) any order, writ. judgment, injunction, decree, determination, or award of
`any court or Governmental Entity presently in effect applicable to Assignee.
`
`c. This Patent Assignment Agreement is a legal, valid, and binding obligation of
`Assignee enforceable against it in accordance with its terms and conditions,
`subject to the effects of bankruptcy, insolvency, or other laws of general
`application affecting the enforcement of creditor rights, judicial principles
`affecting the availability of specific performance, and general principles of
`equity (whether enforceability is considered a proceeding at law or equity).
`
`5. Confidentiality and Non-Disclosure
`
`a. Confidentiality Obligations. At all times until the later of: expiration or
`invalidation ofthe Assigned Patents or for a period of fifteen (15) years
`thereafter, each Party shall, and shall cause its officers, directors. employees
`and agents [including outside counsel and consultants) to, keep confidential
`and not publish or otherwise disclose to a Third Party and not use, directly or
`indirectly. for any purpose, any Confidential information furnished or
`otherwise made known to it. directly or indirectly, by the other Party. except
`to the extent such disclosure or use is expressly permitted by the terms of
`this Patent Assignment Agreement or is necessary or reasonably useful for
`the performance of, or the exercise of such Party's rights under, this Patent
`Assignment Agreement
`
`b. "Confidential information" means any technical, business, or other
`information provided by or on behalf of one Party to the other Party in
`connection with this Agreement, whether prior to, on, or after the Effective
`Date, including any information relating to the terms of this Patent
`Assignment Agreement and any proceeding or claim pertaining to the
`Assigned Patents, any development or commercialization of any product
`covered or claimed by the Assigned Patents. Notwithstanding the foregoing,
`the terms of this Agreement shall be deemed to be the Confidential
`information of both Parties and both Parties shall be deemed to be the
`
`receiving Party and the disclosing Party with respect thereto.
`
`c. Exceptions. Notwithstanding Section 5(a), the confidentiality and non-use
`obligations under Section 5(3) with respect to any Confidential information
`shall not include any information that:
`
`i.
`
`is or hereafter becomes part of the public domain by public use,
`publication, general knowledge or the like through no fault of the
`receiving Party in breach of this Agreement;
`
`ii. can be demonstrated by documentation or other competent proof to
`have been in the receiving Party’s (or its affiliates'] possession prior
`to disclosure by the disclosing Party without any obligation of
`confidentiality with respect to such information;
`
`3
`
`(’4.l3"'fflfi7gl7
`
`
`
`EXECUTION VERSION
`
`iii.
`
`is subsequently received by the receiving Party on a non-confidential
`basis from a Third Party who is not bound by any obligation of
`confidentiality with respect to such information;
`
`iv. has been published by a Third Party or otherwise enters the public
`domain through no fault of the receiving Party in breach of this
`Agreement; or
`
`v. can be demonstrated by documentation or other competent evidence
`to have been independently developed by or for the receiving Party
`without reference to the disclosing Party's Confidential Information.
`
`Specific aspects or details of Confidential information shall not be deemed to
`be within the public domain or in the possession of the receiving Party
`merely because the Confidential Information is embraced by more general
`information in the public domain or in the possession of the receiving Party.
`Further, any combination of Confidential information shall not be considered
`in the public domain or in the possession of the receiving Party merely
`because individual elements of such Confidential Information are in the
`
`public domain or in the possession of the receiving Party unless the
`combination and its principles are in the public domain or in the possession
`ofthe receiving Party.
`
`. Mutual Permitted Disclosures. Each Party may disclose Confidential
`information to the extent that such disclosure is:
`
`i. made in response to a valid order ofa court of competentjurisdiction
`or other Governmental Entity or, if in the reasonable opinion of the
`receiving Party's legal counsel, such disclosure is otherwise required
`by Applicable Law, including by reason of filing with securities
`regulators; provided, however, that the receiving Party shall first have
`given notice to the disclosing Party and given the disclosing Party a
`reasonable opportunity to quash such order or to obtain a protective
`order or confidential treatment order requiring that the Confidential
`Information and documents that are the subject ofsuch order or are
`required by Applicable Law to be disclosed. as applicable. be held in
`confidence by such court or agency or, if disclosed, be used only for
`the purposes for which the order was issued or the disclosure was
`required by Applicable Law, as applicable; and provided, further. that
`the Confidential information disclosed in response to such court or
`governmental order shall be limited to that information that is legally
`required to be disclosed in response to such court or governmental
`order; or
`
`ii. made by or on behalfof the receiving Party or any ofits affiliates to its
`or their attorneys, auditors. advisors, consultants, contractors or any
`
`4
`
`(tail? fil/gfl
`
`
`
`EXECUTION VERSION
`
`Governmental Entities or other Third Parties for use by such Person
`as may be necessary or reasonably useful in connection with the
`performance of the receiving Party’s obligations hereunder or
`exercising the rights and licenses of the receiving Party hereunder;
`provided, however, that such persons (excluding any Governmental
`Entity] shall be subject to obligations of confidentiality and non-use
`with respect to such Confidential Information substantially similar to
`the obligations of confidentiality and non-use pursuant to this
`Section 5, either by written agreement or through professional
`responsibility standards.
`
`6. Recordation and Further Actions.
`
`a. The provisions of Section 5 notwithstanding, Assignor is hereby expressly
`authorized to record and register a summary of this Patent Assignment upon
`request by Assignee or its licensee with the Commissioner for Patents in the
`United States Patent and Trademark Office. Following the date hereof,
`Assignor shall take such steps and actions, and provide such cooperation and
`assistance to Assignee and its successors. assigns, and legal representatives.
`including the execution and delivery ofany affidavits, declarations, oaths,
`exhibits, assignments, powers of attorney. or other documents, as may be
`necessary to effect, evidence, or perfect the assignment of the Assigned
`Patents to Assignee. or any assignee or successor thereto.
`
`b. Assignor covenants and agrees that it will, at any time upon 'request of
`Assignee, without cost or further compensation, execute and deliver any and
`all papers or instruments that, in the reasonable opinion of the Assignee, may
`be necessary or desirable to secure said Assignee the full enjoyment of the
`rights and properties herein conveyed or intended to be conveyed by this
`instrument. subject to the encumbrances identified above.
`
`7. Severabllity. If any provision of this Patent Assignment Agreement is held to be
`illegal, invalid, or unenforceable under any present or future law. and if the rights or
`obligations of either Party under this Patent Assignment Agreement will not be
`materially and adversely affected thereby, (a) such provision shall be fully
`severable, (b) this Patent Assignment Agreement shall be construed and enforced as
`if such illegal, invalid, or unenforceable provision had never comprised a part
`hereof, (c) the remaining provisions of this Patent Assignment Agreement shall
`remain in full force and effect and shall not be affected by the illegal, invalid, or
`unenforceable provision or by its severance herefrom, and (d) in lieu of such illegal,
`invalid, or unenforceable provision, there shall be added automatically as a part of
`this Patent Assignment Agreementa legal. valid, and enforceable provision as
`similar in terms to such illegal, invalid, or unenforceable provision as may be
`possible and reasonably acceptable to the Parties. To the fullest extent permitted by
`Applicable Law, each Party hereby waives any provision of law that would render
`
`E
`any provision hereofillegal, invalid.or unenforceable in any respect.
`Ur j, 9') 4/9”}
`he. (Kg/£1.
`
`5
`
`v
`
`
`
`EXECUTION VERSION
`
`8. Counterparts. This Patent AssignmentAgreement may be executed in two or more
`counterparts, each of which shall be deemed an original, but all of which together
`shall constitute one and the same agreement. This Patent Assignment Agreement
`may be executed by facsimile or electronically transmitted signatures and such
`electronically delivered signatures shall be deemed to have the same legal effect as
`delivery of an original signed copy of this Patent Assignment Agreement.
`
`9. Governing Law and Service; Venue.
`
`a. Governing Law. This Patent Assignment shall be governed by and
`construed in accordance with the laws of the State of New York, excluding
`any conflicts or choice of law rule or principle that might otherwise refer
`construction or interpretation of this Agreement to the substantive law of
`another jurisdiction.
`
`b. Venue. Without limiting Section 12(b), Section 12(d) or Assignor’s rights
`under Section 11, each Party (a) irrevocably submits to the sole and exclusive
`personal jurisdiction of the New York Federal Courts (as defined in Section
`12(b)] and New York State Courts (as defined in Section 12(b)]. generally
`and unconditionally, with respect to any action, suit, arbitration, legal
`process, investigation, claim, proceeding (including enforcement
`proceeding), demand or other similar dispute or dispute resolution method
`[whether federal, state, local or tribal) (each, an "Action") brought by it or
`against it by the other Party; provided that such Action must first be brought
`in New York Federal Courts and only ifNew York Federal Courts do not have
`jurisdiction such Party shall bring such Action in New York State Courts, and
`(b) waives, to the fullest extent it may effectively do so, any objection,
`including any objection to the laying of venue or based on the grounds of
`forum non conveniens or any right ofobjection to jurisdiction on account of
`its place of incorporation or domicile, which it may now or hereafter have to
`the bringing ofany such Action in any New York Federal Court or New York
`State Court.
`
`c. Service. Each Party further agrees that service of any process, summons,
`notice or document by registered mail to its address set forth in
`Section 10(b) shall be effective service of process for any Action brought
`against it under this Patent Assignment Agreement in any such court.
`
`10.Notices.
`
`a. Notice Requirements. Any notice, request, demand, waiver, consent,
`approval, or other communication permitted or required under this Patent
`Assignment Agreement shall be in writing, shall refer specifically to this
`Patent Assignment Agreement and shall be deemed given only if delivered by
`hand or by internationally recognized overnight delivery service that
`maintains records of delivery, addressed to the applicable Party at its
`
`7/W
`
`
`
`HECUTION VERSION
`
`respective address specified in Section 10(b) or to such other address as the
`Party to whom notice is to be given may have provided to the other Party in
`accordance with this Section 10. Such notice shall be deemed to have been
`
`given as ofthe date delivered by hand or transmitted by facsimile (with
`transmission confirmed] or on the second business day [at the place of
`delivery] after deposit with an internationally recognized overnight delivery
`service. Any notice delivered by facsimile shall be confirmed by a hard copy
`delivered as soon as practicable thereafter.
`
`b. Address for Notice.
`
`If to Assignor, to:
`
`lfto Assignee, to:
`
`Allergan, lnc.
`Morris Corporate Center III
`400 lnterpace Parkway
`Parsippany, New Jersey 07054
`Attention: General Counsel
`
`Facsimile: [862) 261-7923
`
`Saint Regis Mohawk Tribe
`412 State Route 37,
`Akwesasne, NY 13655
`Attention: Dale White, Esq.
`General Counsel
`
`Telephone: 518.358.2272
`Email: dale.white@srmt-nsn.gov
`
`11.Dispute Resolution.
`
`
`
`12. Limited Waiver ofSovereign Immunity; Waiver of Tribal Courts and Forums.
`
`8. Limited Waiver of Sovereign Immunity. Neither Assignee nor any
`company, corporation, enterprise, authority, division, subdiviSIon, branch or
`other agency, instrumentality or other government component ofAssignee
`[each ofthe foregoing, including Assignee, a "Tribal Party") consents to any
`Action except that Assignee, on behalfof itselfand each other Tribal Party,
`
`
`
`HECUTION VERSION
`
`expressly and irrevocably waives its and their sovereign immunity (and any
`defense based thereon) from any Action under, in connection with, or
`relating to or arising out of this Patent Assignment Agreement, including the
`performance of, or the exercise of any rights under, this Patent Assignment
`Agreement, subject to the following conditions:
`
`the waiver is expressly limited to Actions brought by Assignor or its
`affiliates or its or their respective successors and permitted assigns
`(collectively. the "Grantees") against Assignee or any other Tribal
`Party with respect to the Transaction Documents and the
`Transactions;
`
`any Action is commenced within three years after the occurrence of
`the facts that are the primary basis of the Action, or iflater, three
`years from the date those facts reasonably should have been
`discovered by the Grantee bringing the Action;
`
`Ill.
`
`iv.
`
`vi.
`
`this limited waiver of sovereign immunity commences on the date
`hereof and continues until the date that is the sixth anniversary of the
`date hereof, provided, however. such limited waiver remains effective
`for any Action pending on the sixth anniversary of the date hereof, all
`appeals therefrom and during the enforcement of any judgments
`resulting therefrom;
`
`any Action shall only be to (A) interpret or enforce the provisions of
`this Patent Assignment Agreement, (B) award any damages or other
`relief in connection with any breach of a this Patent Assignment
`Agreement or any anticipated breach thereof, (C) enforce and execute
`any order, judgment or ruling resulting from such an Action
`(including any other award), or (iv) enforce any rights under the
`lndian Civil Rights Act. 25 U.S.C. § 1301 et seq.;
`
`each Action may seek all available legal and equitable remedies,
`including the right to specific performance, money damages and
`injunctive or declaratory relief; and
`
`no order, judgment. ruling or other remedies related to an Action may
`be enforced against (A) any real property and interests therein,
`including fixtures constituting real property, of a Tribal Party, (B) any
`asset of a Tribal Party against which it would be a violation of federal
`law or state law or any state or federal grant program to enforce
`remedies, (C) any assets belonging to individual members of Assignee.
`or (D) any assets that constitute "Recourse Assets" or any funds held
`in the “Exclusivity Contribution Reserve Account", in each case as such
`terms are defined in that certain Credit Agreement dated as of
`December 28, 2016, among Assignee, certain of its direct and indirect
`
`W
`
`
`
`EXECUTION VERSION
`
`subsidiaries and KeyBank National Association, as amended, restated,
`supplemented or replaced from time to time (collectively. the assets
`described in the foregoing subclauses (ij-(iv) are herein referred to as
`"Prouected Assets”).
`
`b. Consent no jurisdiction of New York Courts. Subject to Sections 12(3) and
`120) and without limiting Section 11(3), Assignee irrevocably and
`unconditionally submits, for itself, each other Tribal Party. and its and their
`respective property, to the exclusive jurisdiction of the United States District
`Court for the Southern District of New York, and any appellate court to which
`any appeals therefrom are available (collectively, the ”New York Federal
`Courts"), or if those courts lack or decline jurisdiction over the action, then
`the Commercial Division of the courts of the State of New York sitting in the
`Borough of Manhattan in New York, New York, and any appellate court to
`which any appeals therefrom are available (collectively, the ”New York State
`Courts”), in any Action under, in connection with, or relating to or arising out
`of this Patent Assignment Agreement or the transactions contemplated
`hereby, or for recognition or enforcement of any judgment or order, and
`Assignee (on behalf of itself and each other Tribal Party) and each Grantee
`irrevocably and unconditionally agrees that all claims in respect of any such
`Action may be heard and determined in such court. Assignee, on behalf of
`itself and each other Tribal Party. agrees that a final judgment in any such
`Action may be enforced by any court ofcompetent jurisdiction and that any
`government or Governmental Entity that has the right and duty under
`Applicable Law may take any and all actioh authorized or ordered by any
`court of competent jurisdiction, inciuding'entering the real property of
`Assignee, in giving effect to any judgment entered.
`
`c. Waiver of Exhaustion of Tribal Remedies. Assignee. on behalf of itself and
`each other Tribal Party. expressly waives, to the fullest extent it may legally
`and effectively do so, any right it may otherwise have to require any Action
`be considered or heard first in any tribal court or forum of Assignee or any
`other Tribal Party, now or hereafter existing, whether because of the
`doctrine of exhaustion of tribal remedies or as a matter of comity or
`abstention.
`
`d. Venue. Assignee, on behalf of itself and each other Tribal Party, irrevocably
`and unconditionally waives, to the fullest extent it may legally and effectively
`do so, any objection that it may now or hereafter have to the laying of venue
`ofany Action under, in connection with, or relating to or arising out ofthis
`Patent Assignment Agreement or the transactions contemplated hereby in
`any New York Federal Court or New York State Court Assignee, on behalf of
`itself and each other Tribal Party, irrevocably waives, to the fullest extent
`permitted by Applicable Law, the defense of an inconvenient forum to the
`maintenance of such Action in any such court.
`
`
`
`EXECUTION VERSION
`
`e. Service of Process. Assignee, on behalf of itself and each other Tribal Party,
`irrevocably consents to service of process made to its General Counsel at the
`address and in the manner specified in Section 12. Nothing in any
`Transaction Document will affect the right of any Party hereto to serve
`process in any other manner permitted by Applicable Law.
`
`f. Enforcement of Judgments. For the purposes of this Patent Assignment
`Agreement, each of the Parties agrees that a final judgment in any Action
`shall be conclusive and may be enforced in other jurisdictions by suit on the
`judgment or in any other manner provided by Applicable Law.
`
`g. Law Governing Waiver of Sovereign Immunity, etc. All Parties agree that
`any Dispute arising under the provisions hereof shall be resolved pursuant to
`the law specified in Section 9(3).
`
`h. Further Agreements Relating to the Limited Waiver of Sovereign
`Immunity. Assignee, on behalf of itself and each other Tribal Party, agrees
`that the limited waiver of sovereign immunity and other waivers described
`in this section are irrevocable and agrees not to revoke or further limit. in
`whole or in part, the limited waiver of sovereign Immunity or the waivers
`described in this section or in any way attempt to revoke or further limit, in
`whole or in part. such limited waiver of sovereign immunity. lf Assignee or
`any other Tribal Party (A) revokes, further limits or attempts to revoke or
`further limit the limited waiver of sovereign immunity described in this
`section, (8) takes any action which is inconsistent with the waivers described
`in this section, or (C) fails to submit to the jurisdiction of the courts as
`described in this section, Assignee. on behalf of itself and each other Tribal
`Party, consents to the entry of appropriate injunctive relief, consistent with
`the terms and conditions of this Patent Assignment Agreement.
`
`i. No Other Waivers of Sovereign immunity. Assignce represents that it has
`not and will not waive its or any other Tribal Party's sovereign immunity in
`relation to any interpanes review or any Other proceeding in the United States
`Patent & Trademark Office or any administrative proceeding that may be
`filed for the purpose of invalidating or rendering unenforceable any Assigned
`Patents. For purposes of this Patent Assignment Agreement. no provision of
`this Patent Assignment Agreement should be interpreted to constitute a
`waiver of Assignee's or any other Tribal Party’s sovereign immunity as to any
`inter partes review or similar proceedings.
`
`13. Entire Agreement; Amendments. This Patent Assignment Agreement, together
`with the Exhibit attached hereto, sets forth and constitutes the entire agreement and
`understanding between the Parties with respect to the subject matter hereof and all
`prior agreements. understandings. promises, and representations, whether written
`or oral. with respect thereto are superseded hereby. Each Party confirms that it is
`not relying on any representations or warranties of the other Party except as
`
`
`
`BIBCUTION VERSION
`
`specifically set forth in this Agreement. No amendment. modification, release. or
`discharge of any term or condition of this Agreement shall be binding on the Parties
`unless in writing and duly executed by an authorized representative of each Party.
`
`[SIGNATURE PAGE FOLLOWS]
`
`ll
`
`1‘!"
`
`
`
`IN WITNESS WH EREOF, Assignor and Assignee have duly executed and delivered this
`Patent Assignment as of the Effective Date.
`
`Allergan. Inc.
`
`Signature:
`
`Name and Title:Widen:—
`
`Date:
`
`AGREED TO AND ACCEPTED:
`
`SAINT REGIS MOHAWK TRIBE
`
`By: @—
`
`Erlc Thompson, Tribal Chief
`Q'P—l 7'
`
`Date:
`
` Beverly Cook
`
`ribal Chief
`Data—ia—
`By:
`AQM—
`
`ichael Conners, Tribal Chief
`
`Date:_i&B—_
`
`l
`
`12
`
`(4‘17“? fl? jr
`
`
`
`EXECUTION VERSION
`
`Exhibit A
`
`Assigned Patients
`
`
`
`
`
`
`
`
`
`
`————-_
`
`-————
`
`——-———
`
`—————_
`
`-——-—_
`
`__-———
`——_—_—
`
`o7.Aug.2013—
`
`————m—
`——————
`
`——-———
`
`——————
`
`”m—
`
`
`-——__-_
`
`
`_—————
`
`
`——--——
`_—_—_W—
`
`
`———_—
`
`
`___——
`[rm—___—
`
`
`—_————
`
`
`us _-———
`
`
`
`-___-—
`-————_
`
`
`___———
`
`
`”m-
`——__—m
`
`
`__————
`
`
`_————
`
`
`
`
`
`
`
`
`
`13
`
`QWT/fl'iée
`
`
`
`MCUTION VENOM
`
`___—_—
`___—m—
`___-_—
`___-_—
`___—_—
`___—_—
`
`_—m—— x
`___—1mm.
`___——
`——m
`
`___—_—
`___—_—
`___-_—
`___—_—
`___—_—
`___—_—
`___—_—
`___—_—
`us ___-—
`us ___——
`___—_—
`___—_—
`___—_—
`___—_-
`
`___—_—
`___—_—
`___—_—
`___—_—
`___—_—
`___—_—
`___—_—
`
`14
`
`4*”
`
`M
`/ H
`
`
`
`EXECUTION VERSION
`
`
`
`
`
`m_————
`
`—_——
`
`
`-—_-——
`—_————
`——————
`_———_—
`
`
`—————
`us —_———
`
`——___-
`
`
`—_—__—
`__———_
`_—————
`
`
`-_————
`_-_—_—
`m—_—_—
`
`
`__m
`——————
`
`"__—
`
`
`—_—_——
`
`15
`
`196/;
`yfit/
`
`
`
`EXECUTION VERSION
`
`Schedule 3a
`
`Settlement Agreements
`
`. Settlement and License Agreement between Allergan, Inc. and Apotex, Inc. and
`Apotex Corp., dated December 15, 2015.
`
`. Settlement and License Agreement between Allergan, Inc. and Argentum
`Pharmaceuticals LLC and KVK-Tech, Inc., dated December 7, 2016.
`
`. Settlement and License Agreement between Allergan, Inc. and TWi Pharmaceuticals.
`Inc. and Ni Pharmaceuticals USA. Inc., dated January 11. 2017.
`
`. Settlement and License Agreement between Allergan. Inc. and Famy Care Limited,
`Lupin Atlantis Holdings S.A.. Lupin Pharmaceuticals, Inc. and Axar Pharmaceuticals,
`Inc., dated August 26. 2017.
`
`
`
`. Covenant Not to Sue. dated August 15, 2017. between Allergan, Inc. and Akorn Inc.,
`Famy Care Ltd., InnoPhanna. Inc., Mylan Pharmaceuticals Inc.. Mylan Inc., and
`Teva Pharmaceuticals USA, Inc.
`
`. Covenant Not to Sue, dated August 27, 2017. between Allergan. Inc. and Akom, Inc.,
`InnoPharma. Inc., Mylan Pharmaceuticals Inc., Mylan Inc., and Teva Pharmaceuticals
`USA, Inc.
`
`. /g
`
`